Is Pacific Biosciences of California (PACB) A Good Investment Choice?
Baron Funds, an asset management firm, published its “Baron Health Care Fund” first quarter 2021 investor letter – a copy of which can be downloaded here. A return of 0.58% was delivered by the fund’s institutional shares for the Q1 of 2021, below both its S&P 500 and Russell 3000 Health Care benchmarks that delivered a 6.17% and 2.14% returns respectively for the same period. You can view the fund’s top 5 holdings to have a peek at their top bets for 2021.
Baron Health Care Fund, in their Q1 2021 investor letter, mentioned Pacific Biosciences of California, Inc. (NASDAQ: PACB), and shared their insights on the company. Pacific Biosciences of California, Inc. is a Menlo Park, California-based biotechnology company that currently has a $6.2 billion market capitalization. Since the beginning of the year, PACB delivered a 25.56% return, impressively extending its 12-month gains to 885.48%. As of April 28, 2021, the stock closed at $33.63 per share.